Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2018
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 01 Mar 2018 Results published in the Cancer Science Journal.
- 05 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.